ANEB - Anebulo Pharmaceuticals, Inc. Stock Price, Fair Value and News

2.30USD+0.09 (+4.07%)Delayed as of 17 May 2024, 02:21 pm ET

Market Summary

USD2.30+0.09

Delayedas of 17 May 2024, 02:21 pm

4.07%

ANEB Stock Price

View Fullscreen

ANEB RSI Chart

ANEB Valuation

Market Cap

57.3M

Price/Earnings (Trailing)

-6.13

Price/Sales (Trailing)

257.28

EV/EBITDA

-11.43

Price/Free Cashflow

-6.45

ANEB Price/Sales (Trailing)

ANEB Profitability

EBT Margin

-2206.68%

Return on Equity

-187.5%

Return on Assets

-155.9%

Free Cashflow Yield

-15.51%

ANEB Fundamentals

ANEB Revenue

Revenue (TTM)

222.8K

Rev. Growth (Yr)

-13.98%

Rev. Growth (Qtr)

-9.85%

ANEB Earnings

Earnings (TTM)

-9.3M

Earnings Growth (Yr)

40.9%

Earnings Growth (Qtr)

39.15%

Breaking Down ANEB Revenue

52 Week Range

2.064.05

(Low)(High)

Last 7 days

-26.3%

Last 30 days

-25.3%

Last 90 days

-22.5%

Trailing 12 Months

-4.7%

How does ANEB drawdown profile look like?

ANEB Financial Health

ANEB Investor Care

Shares Dilution (1Y)

1.17%

Diluted EPS (TTM)

0.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	222.8K	0	0	0
2023	71.1K	92.4K	0	163.5K
2022	0	7.3K	28.6K	49.9K
2021	0	1.0K	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Anebulo Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 18, 2023	english aron r.	gifted	-	-	-300,000	-
Dec 18, 2023	english aron r.	gifted	-	-	300,000	-
Nov 13, 2023	english aron r.	acquired	-	-	300,000	-
Dec 17, 2021	english aron r.	bought	2,634	6.5858	400	-
Dec 14, 2021	english aron r.	bought	2,428	5.895	412	-
Dec 03, 2021	english aron r.	bought	26,685	5.93	4,500	-
Dec 02, 2021	english aron r.	bought	73,330	5.3	13,836	-
May 06, 2021	english aron r.	acquired	4,999,750	7.00	714,250	-
May 06, 2021	english aron r.	acquired	5,000,000	7.00	714,286	-

Which funds bought or sold ANEB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	unchanged	-	179,649	1,145,760	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-10.00	-	-%
May 15, 2024	ADAR1 Capital Management, LLC	sold off	-100	-2,945	-	-%
May 15, 2024	Ikarian Capital, LLC	unchanged	-	71,038	453,064	0.05%
May 15, 2024	22NW, LP	unchanged	-	2,414,830	15,401,300	13.27%
May 15, 2024	BOOTHBAY FUND MANAGEMENT, LLC	unchanged	-	8,540	54,467	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-43.55	-7,281	14,746	-%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-50.00	-1,006,810	1,466,780	0.08%
May 15, 2024	Royal Bank of Canada	reduced	-46.48	-	-	-%
May 13, 2024	UBS Group AG	new	-	413	413	-%

Are Funds Buying or Selling ANEB?

Are funds buying ANEB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ANEB

No. of Funds

Recent SEC filings of Anebulo Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
Mar 08, 2024	4/A	Insider Trading
Mar 01, 2024	4	Insider Trading
Feb 13, 2024	8-K	Current Report
Feb 13, 2024	10-Q	Quarterly Report

Peers (Alternatives to Anebulo Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Anebulo Pharmaceuticals, Inc. News

Latest updates

Anebulo Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2021Q2
Revenue	-9.8%	68,084	75,522	6.00	79,152	8,816	-	-	-
Operating Expenses	-39.7%	1,664,251	2,760,459	2,494,389	2,864,041	3,813,122	2,612,047	2,325,484	2,484,705
S&GA Expenses	-100.0%	-	1,697,787	1,077,230	1,774,699	1,943,202	1,388,271	1,207,343	678,013
R&D Expenses	-29.6%	748,339	1,062,672	1,417,159	1,089,342	1,869,920	1,223,776	1,118,141	-
EBITDA Margin	26.6%	-22.01	-29.99	-53.07	-68.94	-98.33	-171	-668	-3,453
Interest Expenses	87.5%	59,696	31,838	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-2,552,581
EBT Margin	26.6%	-22.07	-30.07	-53.20	-69.10	-98.57	-171	-670	-3,464
Net Income	39.1%	-1,653,542	-2,717,369	-2,495,580	-2,797,971	-3,826,952	-2,611,835	-2,322,742	-29,111,739
Net Income Margin	34.6%	-41.96	-64.17	-126	-162	-213	-275	-930	-29,659
Free Cashflow	17.4%	-1,497,378	-1,813,707	-2,849,246	-2,190,545	-2,609,420	-2,033,922	-1,999,256	-3,497,308

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q2
Assets	-20.1%	6.00	8.00	9.00	12.00	14.00	17.00	20.00	16.00	17.00	19.00	21.00	22.00	4.00	3.00
Current Assets	-21.2%	5.00	7.00	-	12.00	-	-	-	-	-	-	-	-	4.00	3.00
Cash Equivalents	-22.5%	5.00	7.00	9.00	11.00	14.00	16.00	19.00	15.00	17.00	18.00	19.00	20.00	3.00	3.00
Liabilities	-0.3%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	1.00	0.00	11.00	-
Shareholder's Equity	-23.2%	5.00	6.00	8.00	11.00	13.00	16.00	19.00	15.00	17.00	19.00	20.00	21.00	-	-
Retained Earnings	-2.7%	-64.10	-62.40	-59.68	-57.20	-54.71	-51.91	-48.08	-45.47	-43.15	-41.27	-40.20	-38.64	-9.53	-0.18
Additional Paid-In Capital	0.2%	69.00	69.00	68.00	68.00	68.00	67.00	67.00	61.00	60.00	60.00	60.00	60.00	0.00	-
Shares Outstanding	0%	26.00	26.00	26.00	26.00	26.00	26.00	23.00	23.00	23.00	23.00	23.00	23.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	17.4%	-1,497	-1,813	-2,726	-2,849	-2,190	-2,609	-2,033	-1,999	-1,461	-1,198	-777	-3,497	-828	-410	-134	-150
Share Based Compensation	0%	200	200	200	242	224	200	200	227	125	94.00	34.00	115	47.00	21.00	16.00	-
Cashflow From Financing	-	-	-	-	-68.16	-	-248	6,699	-	-	-	-	-	-	-	-	3,176

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ANEB Income Statement

2024-03-31

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Research and development	$ 748,339	$ 1,089,342	$ 3,081,231	$ 4,183,038
General and administrative	915,912	1,774,699	3,887,157	5,106,172
Total operating expenses	1,664,251	2,864,041	6,968,388	9,289,210
Loss from operations	(1,664,251)	(2,864,041)	(6,968,388)	(9,289,210)
Other (income) expenses:
Interest expense	59,696		91,534
Interest income	(68,084)	(79,152)	(198,804)	(92,401)
Other	(2,321)	13,082	(9,384)	39,949
Other income, net	(10,709)	(66,070)	(116,654)	(52,452)
Net loss	$ (1,653,542)	$ (2,797,971)	$ (6,851,734)	$ (9,236,758)
Weighted average common shares outstanding, basic	25,933,217	25,633,217	25,784,853	24,888,916
Weighted average common shares outstanding, diluted	25,933,217	25,633,217	25,784,853	24,888,916
Net loss per share, basic	$ (0.06)	$ (0.11)	$ (0.27)	$ (0.37)
Net loss per share, diluted	$ (0.06)	$ (0.11)	$ (0.27)	$ (0.37)

ANEB Balance Sheet

2024-03-31

Condensed Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Jun. 30, 2023
Current assets:
Cash and cash equivalents	$ 5,147,139	$ 11,247,403
Prepaid expenses	223,676	422,748
Total current assets	5,370,815	11,670,151
Other assets:
Loan commitment fees	624,820
Total assets	5,995,635	11,670,151
Current liabilities:
Accounts payable	384,920	534,545
Accrued expenses	625,401	534,256
Total liabilities	1,010,321	1,068,801
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, no shares issued or outstanding at March 31, 2024 and June 30, 2023
Common stock, $0.001 par value; 50,000,000 and 40,000,000 shares authorized at March 31, 2024 and June 30, 2023, respectively; 25,933,217 and 25,633,217 shares issued and outstanding at March 31, 2024 and June 30, 2023, respectively	25,934	25,634
Additional paid-in capital	69,013,155	67,777,757
Accumulated deficit	(64,053,775)	(57,202,041)
Total stockholders’ equity	4,985,314	10,601,350
Total liabilities and stockholders’ equity	$ 5,995,635	$ 11,670,151

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.

CEO	Mr. Simon J. Allen B.Sc., M.B.A., MBA
WEBSITE	anebulo.com
INDUSTRY	Biotechnology
EMPLOYEES	4

Anebulo Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Anebulo Pharmaceuticals, Inc.? What does ANEB stand for in stocks?

ANEB is the stock ticker symbol of Anebulo Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Anebulo Pharmaceuticals, Inc. (ANEB)?

As of Thu May 16 2024, market cap of Anebulo Pharmaceuticals, Inc. is 57.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANEB stock?

You can check ANEB's fair value in chart for subscribers.

What is the fair value of ANEB stock?

You can check ANEB's fair value in chart for subscribers. The fair value of Anebulo Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Anebulo Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANEB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Anebulo Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether ANEB is over valued or under valued. Whether Anebulo Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Anebulo Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANEB.

What is Anebulo Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, ANEB's PE ratio (Price to Earnings) is -6.13 and Price to Sales (PS) ratio is 257.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANEB PE ratio will change depending on the future growth rate expectations of investors.